Emergent BioSolutions Inc.
NYSE:EBSBiotechnology
-$0.21 today
- Market cap
- $282.78M
- Beta
- 2.33
- P/E (TTM)
- -47.9
- EPS (TTM)
- -$0.17
Volume 0.82M
Average 0.78M
EBS Stock-Based Compensation
Employee pay granted in shares or options; a non-cash expense that dilutes existing shareholders.
Emergent BioSolutions Inc.NYSE: EBS
Stock-Based Compensation · Q1 FY2026 · quarter ended Mar 2026
Stock-based compensation growth accelerates
Q1 FY2026 stock-based compensation of $1.9M rose 26.7% year over year, ahead of the +22.1% change in trailing-twelve-month stock-based compensation. Sequentially, it fell 64.2% from the prior quarter. Over 3 fiscal years it compounded at -28.9% a year.
Context
- Stock-based compensation amounted to 2.2% of revenue in FY2025, up 0.5 pp from a year earlier.
- Stock-based compensation increased in 0 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth of +26.7% holds above the trailing-twelve-month pace of +22.1%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Stock-Based Compensation history
USD · from the cash flow
- Latest · FY2025
- 16.2M USD
- Year-over-year change
- -10.0%
- 4-year CAGR
- -21.4%
| Period | Period end | Stock-Based Compensation | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 16.2M | -10.0% |
| FY2024 | 2024-12-31 | 18M | -22.1% |
| FY2023 | 2023-12-31 | 23.1M | -48.8% |
| FY2022 | 2022-12-31 | 45.1M | +6.4% |
| FY2021 | 2021-12-31 | 42.4M | — |
Stock-Based Compensation vs competitors
How EBS compares with its peers on the latest reported figures
- Peers report in different currencies, so stock-based compensation is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of +22.1% is the 2nd highest of 11, against a peer median of -4.1%.
- Stock-based compensation amounts to 2.5% of revenue for EBS, versus a peer median of 3.8%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $33.61M USD | -24.5% | +6.3% | 58.0% | |
| LTM Mar 2026 | $16.6M USD | +22.1% | -28.9% | 2.5% | |
| LTM Mar 2026 | $13.57M USD | +17.6% | +26.6% | 2.6% | |
| LTM Mar 2026 | $13.21M USD | -40.1% | — | — | |
| LTM Mar 2026 | CA$13.13M CAD | -20.8% | +12.9% | 1.4% | |
| LTM Mar 2026 | $12.84M USD | +21.4% | +0.9% | 4.3% | |
| LTM Mar 2026 | $12.55M USD | -31.5% | +1.2% | — | |
| LTM Mar 2026 | $9.91M USD | -11.7% | -13.4% | 2.4% | |
| LTM Mar 2026 | $8.36M USD | +17.6% | +20.3% | 16.6% | |
| LTM Mar 2026 | $6.73M USD | +88.8% | +25.6% | — | |
| LTM Mar 2026 | $3.53M USD | +3.6% | +27.4% | 3.8% | |
| Peer median (excluding EBS) | — | -4.1% | +12.9% | 3.8% | |
Competitors are the stored peer set for EBS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | 230.9M | (211.6M) | (760.5M) | (190.6M) | 52.6M |
| Depreciation & Amortization | 123.8M | 143.3M | 125.1M | 108.8M | 95.8M |
| Deferred Income Tax | 46.9M | (28.6M) | (8.9M) | (5.5M) | (4M) |
| Stock-Based Compensation | 42.4M | 45.1M | 23.1M | 18M | 16.2M |
| Change in Working Capital | (156.4M) | (2.1M) | (70.3M) | 88.7M | (22.4M) |
| Accounts Receivables | (48.2M) | 118.1M | (21.6M) | (24.4M) | 25.5M |
| Inventory | (44M) | (57.1M) | 600K | (24.5M) | (30.3M) |
| Accounts Payables | (2.5M) | (14M) | 10.6M | (33M) | (8.4M) |
| Other Working Capital | (61.7M) | (49.1M) | (59.9M) | 170.6M | (9.2M) |
| Other Non-Cash Items | 33.5M | 19.8M | 485.2M | 39.3M | 32.4M |
| Operating Cash Flow | 321.1M | (34.1M) | (206.3M) | 58.7M | 170.6M |
| Capital Expenditures | (225M) | (115.8M) | (51.6M) | (22.9M) | (13.8M) |
| Acquisitions (Net) | 0 | 0 | 270.2M | 0 | 0 |
| Purchases of Investments | 0 | 0 | 0 | 0 | 0 |
| Sales of Investments | 0 | 0 | 0 | 0 | 0 |
| Other Investing Activities | 0 | (265.5M) | (6.3M) | 148.1M | 83.2M |
| Investing Cash Flow | (225M) | (381.3M) | 212.3M | 125.2M | 69.4M |
| Debt Repayment | (35.9M) | 564.2M | (543.4M) | (198.4M) | (112.5M) |
| Common Stock Issued | 0 | 0 | 8.4M | 9.3M | 2.2M |
| Common Stock Repurchased | (106M) | (82.1M) | 0 | 0 | (24.9M) |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 900K | (900K) | (700K) | (900K) | (1.4M) |
| Financing Cash Flow | (141M) | 481.2M | (535.7M) | (190M) | (136.6M) |
| Effect of Forex Changes | (300K) | 500K | (1.2M) | 0 | 100K |
| Net Change in Cash | (45.2M) | 66.3M | (530.9M) | (6.1M) | 103.5M |
| Free Cash Flow | 96.1M | (149.9M) | (257.9M) | 35.8M | 156.8M |
Emergent BioSolutions Inc.
NYSE:EBS
Intrinsic Alpha fair value
Locked
Current Price
$5.50
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.